Niagen Bioscience Inc (NAGE)
Niagen Bioscience Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $3.05, up 1.33% on the session, giving a market capitalisation of $242.9M. On trailing twelve-month figures it carries a trailing P/E of 15.71, a net margin of 12.4%. Its beta of 2.09 implies it has historically moved more than the broad market.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Niagen Bioscience Inc is most often compared with the following Healthcare names: